Evidence map›Paper›PMID 27588196›Full record

ArticleMolecular and clinical oncology2016

Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences.

Mohamed Badr, Tamer Hassan, Hanan Sakr, Nehad Karam, Doaa Abdel Rahman, Doaa Shahbah, Marwa Zakaria, Sahbaa Fehr

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. [Glycyrrhetinic acid selectively inhibits proliferation of hepatocellular carcinoma cells in vitro].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohamed BadrDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Tamer HassanDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Hanan SakrDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Nehad KaramDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Doaa Abdel RahmanDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Doaa ShahbahDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Marwa ZakariaDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Sahbaa FehrDepartment of Pediatrics, Faculty of Medicine, Zagazig University, Zagazig, Sharqia 44111, Egypt.
Zagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy-induced neutropenia (CIN) is the major dose-limiting toxicity of systemic chemotherapy and it is associated with significant morbidity, mortality and treatment cost. The aim of the present study was to identify the risk factors that may predispose pediatric cancer patients who receive myelosuppressive chemotherapy to CIN and associated sequelae. A total of 113 neutropenia episodes were analyzed and the risk factors for CIN were classified as patient-specific, disease-specific and regimen-specific, while the consequences of CIN were divided into infectious and dose-modifying sequelae. The risks and consequences were analyzed to target high-risk patients with appropriate preventive strategies. Among our patients, 28% presented with a single neutropenia attack, while 72% experienced recurrent attacks during their treatment cycles. The mean absolute neutrophil count was 225.5±128.5 ×10

Indexed as

chemotherapyconsequencesneutropeniarisks

Identifiers

PMID27588196
PMCPMC4998081
OpenAlexW2476270710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.